DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) critical ailment formulations, is excited to announce the appointment of world renowned Cannabis Cultivator Bret Bogue as Director of Horticulture for the company. Mr. Bogue is a valuable addition to the company, with decades of experience growing cannabis for medical purposes.
Mr. Bogue will play a key role in the development and maintenance of all horticulture operations for the company while developing specific strains for mass production for the company’s growing standards and critical ailment formulations developed by the company. Mr. Bogue will be a part of the lead development team for plants and strains to be used to develop these medical cannabis formulations and products for Cannabis Science.
Being a critical cancer patient himself, Mr. Bogue was diagnosed with a very rare form of melanoma in 1995. Mr. Bogue stated, “I became very ill and was looking for an alternative medication for my illness, so I realized then that I needed to create Apothecary™ Genetics to provide an alternative treatment solution in the early 90s. Through my world travels, I have been able to find ‘land race strains’ and breed them with hybrids to create World Class medical cannabis.”
Bret and Apothecary went on to become the first American-based seed company to win the coveted Cannabis Cup in Amsterdam in 2007, and has won many other international and national awards for his medical cannabis developments. Having over 20 years of experience creating unique medical strains of cannabis, such as Grape Ape aka GDP, Kaia Kush, Sour Grapes, Old School Jams, and Goo, just to name a few, has put Bret and Apothecary Genetics on the world map as one of the top leaders in medical cannabis development.
Mr. Bogue concludes with, “ I was able to cure my melanoma by using medical cannabis in combination with standard radiation treatment. I am the living proof that medical cannabis kills cancer cells.”
As well, Bret is embarking on some exciting new projects such as a documentary with television giant A&E. Two pilots have already been filmed and sent to New York for review and approvals. The documentary will show real patients who are having real, positive results with medical cannabis. These patients include seniors from a senior citizens’ community in California. Viewers will see the reality of the medication’s benefits, as well as the emotions that come into play when someone is chronically ill.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
Investor Relations Management